The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model

References

• The Canadian Cystic Fibrosis Registry: 2011 Annual Report. Cystic Fibrosis Canada. 2011.
   Google Scholar
• Cystic Fibrosis in Australia 2012: 15th Annual Report from the Australian Cystic Fibrosis Data Registry. The Thoracic Society of Australia and New Zealand.
   Google Scholar
• Robinson J. Preventing respiratory syncytial virus infections. Paediatr Child Health 2011; 16(8):488-90.
   Web of Science ®Google Scholar
• Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002; 91(5):593-8; PMID:12113331; http://dx.doi.org/10.1111/j.1651-2227.2002.tb03282.x
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102(3 Pt 1):531-7.
   Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143(4):532-40; PMID:14571236; http://dx.doi.org/10.1067/S0022-3476(03)00454-2
   PubMed Web of Science ®Google Scholar
• Sanchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopath 2015; 43(3):298-303; http://dx.doi.org/10.1016/j.aller.2013.09.003
   PubMed Web of Science ®Google Scholar
• Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J. 2008; 27(6):559-61; PMID:18434935; http://dx.doi.org/10.1097/INF.0b013e3181673c15
   PubMed Web of Science ®Google Scholar
• Giebels K, Marcotte J-E, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43(2):169-74; PMID:18085710; http://dx.doi.org/10.1002/ppul.20751
   PubMed Web of Science ®Google Scholar
• McCormick J, Southern KW. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Chil 2007; 92(1):87-8; PMID:17185451; http://dx.doi.org/10.1136/adc.2006.0105338
   PubMed Web of Science ®Google Scholar
• Sorrentino M, Powers T, Grp POS. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J. 2000; 19(11):1068-71; PMID:11099087; http://dx.doi.org/10.1097/00006454-200011000-00007
   PubMed Web of Science ®Google Scholar
• Paes B, Mitchell I, Li A, Lanctot KL. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 2012; 171(5):833-41; PMID:22203430; http://dx.doi.org/10.1007/s00431-011-1654-8
   PubMed Web of Science ®Google Scholar
• Cohen A, Boron M. C. D. A phase IV study of the safety of Synagis (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. American Thoracis Society International Conference; 2005; San Diego, CA.
   Google Scholar
• Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998; 26(6):371-9; PMID:9888211; http://dx.doi.org/10.1002/(SICI)1099-0496(199812)26:6%3c371::AID-PPUL1%3e3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984; 311(26):1653-8; PMID:6504106; http://dx.doi.org/10.1056/NEJM198412273112602
   PubMed Web of Science ®Google Scholar
• Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009; 25(7):1585-91; PMID:19469698; http://dx.doi.org/10.1185/03007990902929112
   PubMed Web of Science ®Google Scholar
• Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2014; 5:CD007743; PMID:24851825
   PubMedGoogle Scholar
• Borowitz D, Robinson KA, Rosenfeld M, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155(6 Suppl):S73-93; PMID:19914445; http://dx.doi.org/10.1016/j.jpeds.2009.09.001
   PubMed Web of Science ®Google Scholar
• Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2):415-20; PMID:25070315; http://dx.doi.org/10.1542/peds.2014-1665
   PubMed Web of Science ®Google Scholar
• Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol 2009; 44(1):96-98; PMID:19085922; http://dx.doi.org/10.1002/ppul.20922
   PubMed Web of Science ®Google Scholar
• van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 2013; 16(2):345-55; PMID:23538187; http://dx.doi.org/10.1016/j.jval.2012.12.003
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Data Network: National and International Cystic Fibrosis Data Reports. 2013; http://www.cysticfibrosisdata.org/Reports.htm. Accessed June 12, 2015.
   Google Scholar
• Synagis prescribing information. 2014; http://www.medimmune.com/docs/default-source/pdfs/prescribing-information-for-synagis.pdf. Accessed June 12 2015.
   Google Scholar
• Collinson J, Nicholson KG, Cancio E, Ashman J, Ireland DC, Hammersley V, Kent J, O'Callaghan C. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 1996; 51(11):1115-22; PMID:8958895; http://dx.doi.org/10.1136/thx.51.11.1115
   PubMed Web of Science ®Google Scholar
• Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 1995; 73(2):117-20; PMID:7574853; http://dx.doi.org/10.1136/adc.73.2.117
   PubMed Web of Science ®Google Scholar
• Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988; 113(5):826-30; PMID:3183835; http://dx.doi.org/10.1016/S0022-3476(88)80008-8
   PubMed Web of Science ®Google Scholar
• Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999; 103(3):619-26; PMID:10049966; http://dx.doi.org/10.1542/peds.103.3.619
   PubMed Web of Science ®Google Scholar
• Garcia DF, Hiatt PW, Jewell A, Schoonover SL, Cron SG, Riggs M, Grace S, Oermann CM, Piedra PA. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol 2007; 42(1):66-74; PMID:17123316; http://dx.doi.org/10.1002/ppul.20546
   PubMed Web of Science ®Google Scholar
• Yi MS, Britto MT, Wilmott RW, Kotagal UR, Eckman MH, Nielson DW, Kociela VL, Tsevat J. Health values of adolescents with cystic fibrosis. J Pediatr 2003; 142(2):133-40; PMID:12584533; http://dx.doi.org/10.1067/mpd.2003.51
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995; 108(6):1594-601; PMID:7497767; http://dx.doi.org/10.1378/chest.108.6.1594
   PubMed Web of Science ®Google Scholar
• Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009; 35(1):4; PMID:19490659; http://dx.doi.org/10.1186/1824-7288-35-4
   PubMed Web of Science ®Google Scholar
• The Ontario Case Costing Initiative. http://www.occp.com/mainPage.htm. Accessed Nov 15, 2013.
   Google Scholar
• Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M. Economic appraisal of ontario's universal influenza immunization program: A cost-utility analysis. PLoS Med 2010; 7(4):e1000256; PMID:20386727; http://dx.doi.org/10.1371/journal.pmed.1000256
   PubMedGoogle Scholar
• Calo-Fernandez B, Martinez-Hurtado JL. Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals (Basel). 2012; 5(12):1393-408; PMID:24281342
   PubMedGoogle Scholar
• Robinson KA, Odelola OA, Saldanha I, McKoy N. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2010; (2):CD007743; PMID:20166098
   PubMedGoogle Scholar
• Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009; 12(4):361-70; PMID:19900071; http://dx.doi.org/10.3111/13696990903442155
   PubMedGoogle Scholar
• Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008; 24(11):3223-37; PMID:18928643; http://dx.doi.org/10.1185/03007990802484234
   PubMed Web of Science ®Google Scholar
• Bentley A, Filipovic I, Gooch K, Busch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev 2013; 3(1):18; PMID:23919494; http://dx.doi.org/10.1186/2191-1991-3-18
   PubMedGoogle Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - The curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014; 371(9):796-7; PMID:25162885; http://dx.doi.org/10.1056/NEJMp1405158
   PubMed Web of Science ®Google Scholar
• Dieticians of Canada. WHO Growth Charts for Canada. Birth to 24 Months: Boys. 2010.
   Google Scholar
• Cystic Fibrosis Canada. Canadian Cystic Fibrosis Patient Data Registry Report. Toronto, ON: Cystic Fibrosis Canada, 2010.
   Google Scholar